The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
Dec 02, 2024•over 1 year ago
Contract Type
partnership
Santa AnaBiotechnologyHealth Care
Description
NKGen Biotech has been selected as the preferred stalking horse bidder for NKMax Co., Ltd. in NKMax’s court-managed rehabilitation process in South Korea. The acquisition is expected to put global rights under the control of NKGen and may accelerate production for US trials.
Company Information
Company
NKGen Biotech
Location
Santa Ana, California, United States
About
NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative natural killer cell therapeutics. The company is actively pursuing treatments for neurodegenerative disorders and various cancers. NKGen aims to bring therapies like troculeucel to market, enhancing patient care and shareholder value. Their strategic goal includes maintaining partnerships to advance clinical programs and achieve regulatory approvals in relevant markets.
Santa AnaBiotechnologyHealth Care